Autoimmune hemolytic anemia as an initial manifestation of Hodgkin’s Disease: Case report by Urrego-Díaz, José Augusto et al.
551Rev. Fac. Med. 2016 Vol. 64 No. 3: 551-3
Autoimmune hemolytic anemia as an initial manifestation 
of Hodgkin’s Disease: Case report
Anemia hemolítica como manifestación inicial de la enfermedad
de Hodgkin. Reporte de caso
Received: 14/12/2015.  Accepted: 28/12/2016.
José Augusto Urrego-Díaz1 • Carlos Javier Lozano-Triana2 • Guillermo Landínez-Millán2 • Agustín Darío Contreras-Acosta3 
1  Universidad Nacional de Colombia - Bogotá Campus - Faculty of Medicine - Bogotá, D.C. - Colombia.
2  Universidad Nacional de Colombia - Bogotá Campus - Faculty of Medicine - Department of Pediatrics - Bogotá, D.C. - Colombia.
3  Fundación Hospital de la Misericordia - Pediatric Oncohematology Unit - Bogotá, D.C. - Colombia. 
Corresponding author: José Augusto Urrego-Díaz, Universidad Nacional de Colombia, Faculty of Medicine, Department of Pediatrics. 




This paper presents the case of an 11 year-old male who attended the 
Internal Medicine Service at a high complexity pediatric hospital.
Initially, the patient attended due to a clinical profile consisting 
of autoimmune hemolytic anemia that was partially responsive to 
steroid treatment and, after exhaustive complimentary analysis, 
was associated to a Hodgkin lymphoma. Similar cases found in the 
scientific literature were reviewed in order to analyze this case. 
Through this paper, the authors intend to remind the medical 
community about the importance of a prompt and deep study of 
all autoimmune hemolytic anemia cases found in pediatric patients, 
without overlooking possible malignant causes related to this condition 
such as a lymphoproliferative disorder. Thus, before diagnosing a 
hemolytic anemia as idiopathic, the practitioner must be certain that 
the condition is  not a clinical manifestation of an underlying disease. 
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| Resumen |
Se presenta el caso de un niño de 11 años atendido en el servicio 
de Medicina Interna de una institución pediátrica de alto nivel de 
complejidad. 
El paciente consultó por un cuadro de anemia hemolítica autoinmune 
que respondió parcialmente al tratamiento con esteroides y luego de 
los estudios complementarios se encontró asociada a un linfoma 
Hodgkin. Se revisaron casos similares en la literatura y se hizo un 
análisis al respecto. 
A través de este artículo se recuerda e insiste en que toda anemia 
hemolítica en niños se debe estudiar de forma pronta, profunda y 
sin descuidar posibles causas malignas relacionadas como una 
enfermedad linfoproliferativa; por lo tanto, antes de declarar una 
anemia hemolítica como idiopática, se debe estar seguro de que no 
se trata de una expresión clínica de otra enfermedad de base. 
Palabras clave: Anemia; Anemia hemolítica; Enfermedad de Hodgkin 
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Introduction
Autoimmune hemolytic anemia (AHA) is a relatively rare disease with 
an annual incidence of 1 per 75 000 to 80 000 people. The average age 
of diagnosis is 3.8 years in the pediatric population (1). For decades, 
autoimmune entities such as hemolytic anemia, thrombocytopenic 
purpura, neutropenia and insulin receptor antibodies have been 
reported as paraneoplastic manifestations of Hodgkin’s disease (HD) 
(1-4). Therefore, all patients with AHA should be studied to discover 
the cause and to discard the presence of neoplastic based entities such 
as HD and non-neoplastic entities such as infections, autoimmune 
diseases, drug intake, etc. (5).
The development of autoimmune hemolytic anemia in 
lymphoproliferative disorders is multifactorial and caused by 
disorders in regulatory and autoreactive LB and LT (6) cells. The 
Hodgkin lymphoma implies alterations in the immune system, which 
include abnormalities in the cytokine production and increased 
sensitivity to regulatory T cells, but with an overall decrease in 
the number and functional capacity of T cells (6-8). Thus, during a 
decrease of cytotoxic T lymphocytes, an increase in autoantibody 
production may occur; this is currently the most accepted mechanism 
to explain the appearance of AHA in some of these patients (9).
In the past, based on epidemiological studies, the hypothesis of a 
possible infectious etiology during HD that instigates the production of 
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antibodies that cross-react with antigens in the erythrocyte membrane 
(10,11) was proposed, however, this theory has not been proven yet.
This paper describes the case of a pediatric patient who developed 
hemolytic anemia as an initial manifestation of Hodgkin lymphoma; 
this finding is highlighted as a paraneoplastic manifestation of HD 
that should be taken into account when studying the causes of AHA. 
Case presentation
Male patient, 11 years old, with a history of anemia of 10 months 
which was diagnosed in a control consultation, with unclear 
characteristics and etiology, and managed with ferrous sulfate.
On admission in hospital, the relatives referred fever peaks of 
up to 39°C, predominantly nocturnal, associated with asthenia, 
adynamia and unquantified weight loss. Physical examination 
showed a thin aspect and muco-cutaneous pallor. A complete blood 
count found hemoglobin at 7.4 g/dL, mean corpuscular volume 
of 77.7fl and mean corpuscular hemoglobin of 25.9pg; the blood 
smear showed moderate anisocytosis with presence of dacrocytes 
and codocytes. The patient was hospitalized under the diagnosis of 
normocytic normochromic anemia of unclear etiology; studies were 
extended and a direct Coombs test, with positive results (+++), and 
a high LDH were performed, which finale led to conclude that the 
patient presented immune hemolytic anemia. 
The fever and weight loss manifestations suggested a neoplasm 
as the cause of the immune hemolytic anemia; therefore, further 
studies, such as chest radiography and abdominal ultrasound, 
were performed. The first exam showed no alterations and the 
second showed para-aortic lymphadenopathy and left iliac chain, 
as well as hypo-echoic images in the common left iliac artery. A 
biopsy and bone marrow aspiration were also performed, which 
reported no tumor infiltration. Due to the presence of an acute 
hemolytic picture, treatment with methylprednisolone 30 mg/kg/
day for three days was ordered; after this, a control complete 
blood count was performed, in which an increase in the value of 
Hb 8.9g/dL was found. Treatment was continued with prednisone 
at 1 mg/kg/day.
The studies initially performed to find a possible infectious, 
tumor and autoimmune disease causes were negative. The patient 
persisted with spiking fevers and presented painful hepatomegaly 
during the clinical evolution, so a new abdominal ultrasound 
was requested, in which enlarged lymph nodes in the para-aortic 
region with involvement of the left iliac region were found. The 
child was further evaluated through pediatric surgery for lymph 
node biopsy; the pediatric surgeon ordered complementary studies 
including an abdominal computed tomography scan that reported 
lymphadenopathies in the left iliac chain with ipsilateral para-aortic 
region involvement. Based on these findings, a magnetic resonance 
imaging of the abdomen and pelvis was ordered, which showed 
splenomegaly, nodes in the para-aortic region, left infrarenal aortoiliac 
bifurcation and solid smooth masses accompanying the major vessels 
and the lower region of the renal hilum, compatible with neoplasia.
A biopsy of the retroperitoneal lymph node showed infiltration of 
Reed Stemberg cells with positive reactivity in immunohistochemistry 
for CD15, CD30, PAX-5 and LMP-1 studies, which confirmed the 
diagnosis of a mixed cellularity Hodgkin disease. The clinical status 
corresponded to stage IIB, for which chemotherapy with ABVD 
scheme was started.
The patient received six cycles of ABVD chemotherapy 
(doxorubicin, bleomycin, vinblastine and dacarbazine) and subsequent 
consolidation treatment with radiotherapy in sites involved at diagnosis. 
At the end of the study, the child was in clinical remission for two 
years, with control blood counts within normal limits, and monitoring 
and control through the oncohematology service.
Discussion
Previously, prevalence of autoimmune hemolytic anemia has 
been reported in patients with Hodgkin’s disease ranging between 
0.2% and 2.7% (2,12); with the development of more sensitive 
immunoassays, it is likely that a larger number of HD patients are 
being diagnosed with AHA (13). However, this type of anemia as 
the first manifestation of this disease is even more unusual than their 
mere association (10,14).
Bowdler & Glick (15) first published about this relationship, 
stressing that the diagnosis of AHA preceded by three years the 
dignosis of HD, as in the case of this patient, who had anemia for 10 
months before diagnosis of Hodgkin lymphoma.
The secondary AHA, besides presenting the characteristic clinic 
of hemolytic anemia such as dyspnea, fatigue, paleness or jaundice, 
among others, are presented along with the underlying disease 
clinic. In the case of a lymphoproliferative syndrome, associated 
manifestations usually include appetite and weight loss, night 
sweats, lymphadenopathy and hepatosplenomegaly; this clinic is 
important because it directs or allows suspecting a neoplastic entity 
(6,14,16), as in this patient. Moreover, even in the absence of clinical 
manifestations suggestive of a lymphoproliferative syndrome as the 
cause of autoimmune hemolytic anemia, this type of pathologies 
should always be sought once the diagnosis is made, as well as other 
possible causes (Table 1) (16,17).
Autoimmune hemolytic anemia may be present at any stage of 
Hodgkin’s disease; although it is usually associated with the active 
or advanced disease, it can precede the diagnosis or be present in a 
relapse episode (1,10). A positive Coombs test can be an indicator 
to suspect possible relapses in patients with a history of HD in 
remission with or without AHA (6,10).
Currently, there are no studies of sufficient quality to establish 
appropriate protocols for the management of AHA, nor a consensus 
on what complete remission or partial remission of the disease 
means (19), therefore, the management of hemolytic autoimmune 
anemia is based on experience and individual clinical decisions.
It should be noted that the effectiveness of therapies for AHA 
is low when it is secondary to an underlying disease, this being 
especially true for autoimmune hemolytic anemias secondary to 
lymphoproliferative syndromes (6,13).
The above statement was evident in the case reported here, 
in which no adequate response to treatment with corticosteroids 
was obtained. Definitive therapy for autoimmune hemolytic 
anemia associated with Hodgkin’s disease is the treatment of the 
underlying disease, through which there is a progressive decrease 
of antibody titers until reaching the eventual negativization of the 
Coombs test (20), the recovery of Hb values and the disappearance 
of hemolysis signs.
Conclusions
Autoimmune hemolytic anemia, although unusual, can be a 
paraneoplastic manifestation of a lymphoproliferative syndrome as 
Hodgkin’s disease. The underlying cause of AHA must always be 
sought, even if it is refractory to treatment. Additionally, if there is 
an AHA in a patient with a history of HD in remission, HD should 
be suspected and a relapse should be discarded.
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